



Market release

24 May 2017

NOTICE OF OFFER OF FINANCIAL PRODUCTS OF SAME CLASS AS QUOTED FINANCIAL PRODUCTS

Pursuant to clause 20(1)(a) of schedule 8 to the Financial Markets Conduct Regulations 2014 and ASIC instrument 17-0485

1. AFT Pharmaceuticals Limited ("**AFT**") is making an offer of ordinary shares for issue under a share purchase plan in reliance on the exclusion in clause 19 of schedule 1 of the Financial Markets Conduct Act 2013 ("**FMCA**") and without disclosure to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (Australia) ("**Corporations Act**").
2. This notice is provided under clause 20(1)(a) of schedule 8 of the Financial Markets Conduct Regulations ("**Regulations**") and in accordance with ASIC Instrument 17-0485.
3. At the date of this notice:
 - (a) AFT is in compliance with the continuous disclosure obligations (as defined in the Regulations) that apply to it in relation to the ordinary shares in AFT;
 - (b) AFT is in compliance with its financial reporting obligations (as defined in the Regulations);
 - (c) AFT has complied with its obligations under rule 1.15.2 of the listing rules of ASX Limited; and
 - (d) there is no information that is "excluded information" (as defined in the Regulations).
4. The offer and the acquisition of ordinary shares under the offer will not have any material effect or consequence on the control (as defined in the FMCA) of AFT.

[End of release]

For more information:
Malcolm Tubby
CFO, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232